October 12, 2011New England Journal of Medicine162 citations

Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis

ATAyalew Tefferi MLMark R. Litzow APAnimesh Pardanani

Key Points

Key points are not available for this paper at this time.

Abstract

The initial encouraging activity of ruxolitinib in myelofibrosis appears to need some caveats when long-term efficacy is examined. The control of splenomegaly may not be durable, and the likelihood of leukemic progression or death is not dramatically lowered.

问 AI

Bookmark

View Full Paper

Cite This Study

Tefferi et al. (Wed,) studied this question.

synapsesocial.com/papers/6a5d7735baa8fa97d3c505c5 https://doi.org/https://doi.org/10.1056/nejmc1109555

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status2010 · 1,048 citations
2International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)2006 · 314 citations
3Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis2010 · 1,171 citations
4Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study2011 · 596 citations
5Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival2008 · 251 citations

问 AI

Bookmark

View Full Paper